Abstract：
Both bullous pemphigoid (BP) and psoriasis are common immune-related dermatological conditions in clinical practice, but the co-occurrence of these two diseases is rare. Currently, there is no consensus on the long-term safe and effective treatment for patients with both BP and psoriasis. JAK inhibitors are emerging as targeted therapeutic drugs that act by inhibiting Janus kinase activity, regulating the JAK/STAT pathway, blocking the transduction pathway of key proinflammatory cytokines, and influencing T-cell differentiation. These cytokines upstream of the JAK/STAT pathway play a pivotal role in the pathogenesis of numerous inflammatory and autoimmune disorders. Upadacitinib, a second-generation JAK inhibitor with high selectivity, demonstrates promising potential.This case report aims to provide a description of the successful treatment of bullous pemphigoid (BP) and psoriasis vulgaris by using upadacitinib, highlighting significant clinical outcomes. Additionally, we aim to analyze the underlying mechanism of upadacitinib in treating these two comorbidities by reviewing relevant literature from both domestic and international sources. Based on our clinical observations, upadacitinib appears to be a promising and well-tolerated therapeutic option for patients with concurrent BP and psoriasis, offering valuable insights for developing appropriate treatment strategies in clinical practice.
摘要：
大疱性类天疱疮（BP）和银屑病都是临床实践中常见的免疫相关皮肤病，但是这两种疾病的同时发生很少。目前,对于BP和银屑病患者的长期安全有效治疗尚无共识.JAK抑制剂正在成为通过抑制Janus激酶活性起作用的靶向治疗药物，调节JAK/STAT途径，阻断关键促炎细胞因子的转导途径，影响T细胞分化。JAK/STAT途径上游的这些细胞因子在许多炎性和自身免疫性疾病的发病机理中起关键作用。Upadacitinib,第二代高选择性JAK抑制剂，显示出有希望的潜力。本病例报告旨在描述使用upadacitinib成功治疗大疱性类天疱疮（BP）和寻常型银屑病，突出显著的临床结果。此外,我们旨在通过回顾国内外相关文献,分析upadacitinib治疗这两种合并症的潜在机制.根据我们的临床观察,upadacitinib似乎是并发BP和银屑病患者的一种有希望且耐受性良好的治疗选择,为在临床实践中制定适当的治疗策略提供有价值的见解。
